For the risk stratification of indeterminate thyroid nodules
For the risk stratification of indeterminate thyroid nodules
Please visit us at ENDOExpo 2024 (Booth 626)
In a patient with an indeterminate thyroid nodule and no identified mutations, the use of microRNA signatures helped inform a high risk of malignancy. This clinical case highlights how microRNA profiling, when combined with mutational analysis, can provide deep insights to help improve the risk stratification of indeterminate thyroid nodules.1-3 Clinical Case Overview A 48-year-old […]
At the United States and Canadian Academy of Pathology’s 115th Annual Meeting, Poster #14 presented new real-world data that demonstrated the effectiveness of the ThyGeNEXT® + ThyraMIR®v2 combination testing platform in helping guide appropriate management decisions—supporting either surveillance or surgery—for patients with indeterminate thyroid nodules.1 Study Overview This retrospective study evaluated 334 consecutive patients in
Insights on Real-world Data of Molecular Testing for Indeterminate Thyroid Nodules Read More »
The management of indeterminate thyroid nodules— i.e., nodules classified as Atypia of Undetermined Significance (Bethesda III) and Follicular Neoplasm (Bethesda IV)— continues to pose a substantial diagnostic challenge and often creates uncertainty in clinical decision-making.1 Historically, this uncertainty has led to diagnostic thyroid surgery for many patients with indeterminate cytology, potentially resulting in unnecessary procedures
Confidently Risk-stratify Indeterminate Thyroid Nodules with ThyGeNEXT+ThyraMIRv2 Read More »
A real-world observational study provided data supporting the high performance of the ThyGeNEXT®+ThyraMIR®v2 combination testing platform for evaluating cytologically indeterminate thyroid nodules.1 The performance metrics aligned with the most recent clinical validation study, helping reinforce the utility of this combination approach in everyday clinical settings.
Observational Study Performance Aligns with Clinical Validation Study Read More »
At the 2025 American Thyroid Association® (ATA) meeting, poster #477 presented findings from a retrospective analysis of 28,144 indeterminate thyroid nodules classified as Atypia of Undetermined Significance (B-III) and Follicular Neoplasm (B-IV). These samples, collected between September 2022 and April 2025, were evaluated using the combined ThyGeNEXT®+ThyraMIR®v2 molecular testing platform.
At the 2025 American Thyroid Association® (ATA) Annual Meeting, an exciting poster presentation showcased how a leading healthcare system helped improve their management of cytologically indeterminate thyroid nodules by switching to the ThyGeNEXT®+ThyraMIR®v2 combination testing. Their goal was to help address the high molecular insufficiency rates they experienced with a different molecular test and benefit from more flexible specimen requirements—two major challenges in thyroid nodule testing.
2025 Annual Meeting of the ATA® Poster Insights on Thyroid Nodule Testing Read More »